The dual-marker approach involving ANKRD22 and SERPING1 shows promising clinical utility as a potential predictor of tuberculosis drug resistance, offering novel perspectives for improving diagnostic timelines and treatment strategies in drug-resistant TB management. Here, SERPING1 is linked to tuberculosis.